Erectile dysfunction is increasingly common with over half of men between the ages of 40 and 70 years experiencing it to some degree. This means there are several million men in the UK suffering from ED and the numbers increase with age. However, only a small percentage of sufferers actually receive treatment.
Until recently it was thought to be almost entirely due to psychological causes. However research has shown that hat physical causes are more likely, and the most common of these is disease of the blood vessels which supply blood to the penis (atherosclerosis).
We provide the latest technology in the treatment of vascular erectile dysfunction.
Focused shockwave is a non-invasive procedure for the treatment of vascular erectile dysfunction. The use of punctiform and lateral, linearly focused shockwaves had shown good results in the treatment of vascular erectile dysfunction (ED). Based on sufficient evidence, low-energy focused shockwave therapy is one of the first-line therapies in the EAU guidelines. However, the widespread introduction of this method failed due to the less homogeneous and time-consuming application of the shock wave energy in the erectile tissue.
The advancement of piezo technology, using a therapy source with a linear focusing, voluminous therapy focus, was the decisive breakthrough. In conjunction with the new optimised therapy concept of the LSTC-ED (Syn Volume ESWT-ED), the application technique and the therapeutic results were significantly improved.
The linearly focused shockwave in combination with a piezo therapy source makes it possible for the first time to quickly and comprehensively treat the entire course of the corpora cavernosa. We have devoted the utmost care to the research and clinical release of this procedure. A prospective, multi centre placebo-controlled study of 75 patients showed a marked improvement in the IIEF-5 score and successful treatment in 81% of patients after one month of treatment. Functional improvement was demonstrated 6 months after treatment and demonstrates the long-term effect of LSTC-ED treatment.